NCT05519293View on ClinicalTrials.gov

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

H002

Small molecule, Capsule

Trial Locations (4)

10032

RECRUITING

Columbia University, New York

22031

RECRUITING

NEXT Virginia, Fairfax

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

RedCloud Bio

INDUSTRY